499 Illinois Suite 500
About Vir Biotechnology
Vir is looking for talented individuals who are passionate about creating a world without infectious disease.
Founder: Klaus Frueh and Rober Nelsen
CEO: George Scangos
Please click here for Vir job opportunities.
17 articles with Vir Biotechnology
Vir has granted the underwriters a 30-day option to purchase up to 1,071,428 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Vir Biotechnology Inc. andAlnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B virus (HBV) infection.
Johnson & Johnson’s JLABS incubator in San Francisco recently convened a meeting of biopharma industry executives. One of the hot topics for one of the panels was the competition for talent.
Brii Biosciences is one of many China-based companies that are heavily investing in U.S. biotech and pharmaceutical companies to support the development of programs that could come back to China for approval.
10/9/2018Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association.
Gilmore O’Neill, formerly Biogen’s senior vice president, late-stage clinical development, jumped ship and will be Sarepta Therapeutics’ chief medical officer.
Brii Biosciences Launches with $260 Million, a Partnership with Vir Biotech, and Other Relationsh...
5/24/2018Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.
Pharmaceutical execs who leave their positions with big pharmaceutical companies, unless opting to retire for good, often move to leadership positions at other big companies. There are other choices.
Despite raised awareness over the past few years, the gender diversity gap in the boardrooms of Fortune 1000 companies has remained at slightly less than 20 percent, as of 2017. There is evidence though that shows companies with more diversity at the highest levels see a higher return on investme...
Vir Biotechnology Appoints Leading Immunologist Antonio Lanzavecchia, M.D., Senior VP, Senior Research Fellow
Reporting to CEO George Scangos, Ph.D., Dr. Lanzavecchia will provide scientific leadership for Vir's technical programs that are designed to transform the care of people with serious infectious diseases.
Vir Biotechnology Appoints Herbert W. “Skip” Virgin Executive Vice President and Chief Scientific Officer
The appointment is effective January 1, 2018.
WIB launched Boardroom Ready in 2016.
10/25/2017The former Biogen CEO is making waves at his new venture, Vir Biotechnology.
Two weeks after securing more than $46M in financing, Visterra struck a deal worth up to $1B with startup Vir Biotech.
Vir Biotechnology Builds Pipeline, Capabilities, And Lays Out Strategy To Address Serious Infectious Diseases
Vir Biotechnology, Inc. today announced agreements with Humabs BioMed SA, Alnylam Pharmaceuticals, Inc., and Visterra, Inc., as well as four leading academic research institutions.
Alnylam and startup Vir Biotech inked a deal worth up to $1B for the development and marketing of RNAi therapies aimed at treating infectious diseases including HBV.